NAIROBI (Thomson Reuters Foundation) - A daily dose of anti-HIV medication almost eradicates the risk of infection for people in a relationship with an HIV positive partner, a study showed on Tuesday, ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by 2nd February next year. If approved, the oral ...

Infectious diseases specialist Kevin Rebe spoke to Bhekisisa editor Mia Malan about the do’s and don’ts of pre-exposure prophylaxis, known as PrEP. Rebe heads up Anova Health Institute’s PrEP ...

Subscribe to our newsletter and stay updated on the latest developments and special offers!

The Iranian government does not fund pre-exposure prophylaxis (PrEP), and it is not used in Iran due to uncertainties in its cost-effectiveness. In this study, we examined the cost-effectiveness of ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...